{"classes":[{"categories":[{"measurements":[{"comment":"Values were non-estimable (insufficient number of participants with events).","groupId":"OG000","lowerLimit":"60.0","upperLimit":"NA","value":"61.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"description":"OS was defined as time from first dose to the time of death due to any cause. Participants who were known to be alive or are lost to follow-up were censored at the last time point they were known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEDIAN","populationDescription":"Safety Population: all participants who received ≥1 dose of avapritinib.","reportingStatus":"POSTED","timeFrame":"Baseline through Month 65","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}